Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $474.23 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jan Malcolm, a Director of United Therapeutics Corp (UTHR), reported a sale of common stock.
• The transaction involved the disposition of 50 shares of common stock.
• The shares were sold at a price of $474.23 per share.
• The sale occurred on February 3, 2026.
• Following this transaction, Jan Malcolm directly beneficially owns 270 shares of common stock.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was entered into by the reporting person on September 11, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-established plan, which typically carries a neutral sentiment as it is not indicative of new information or a change in outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are common practice for corporate directors and executives, designed to allow for pre-scheduled stock transactions to avoid accusations of trading on material non-public information. Such routine sales typically do not signal significant shifts in company or industry outlook.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider sale of a relatively small number of shares, not typically signaling a change in company fundamentals or outlook.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan